Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer

Last updated: August 1, 2018
Sponsor: Yonsei University
Overall Status: Active - Recruiting

Phase

2

Condition

Recurrent Ovarian Cancer

Ovarian Cysts

Treatment

N/A

Clinical Study ID

NCT03618706
4-2018-0299
  • Ages > 19
  • All Genders

Study Summary

This study aims to investigate the effect of involved-field radiotherapy for recurrent ovarian cancer after primary standard treatment. We will investigate whether the addition of involved-field RT improves 2-year PFS in those patients than that of historical data (only with other standard salvage treatments as systemic chemotherapy ± maximum tumor resection).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Pathologically confirmed ovarian carcinoma

  • Patients who received "standard treatment" for each stage as a primary treatment

  • No. of recurrent lesions: If, all in lung, or intra-abdominal or pelvis organs - ≤ 5 If, any in liver, bone, orspinal cord - ≤ 2

  • Size of recurrent lesions ≤5 cm

  • All recurrent lesions are available for involved-field radiotherapy

  • Within 60 days before enrollment:

  • Absolute neutrophil count ANC ≥ 500 / mm3

  • Platelet ≥ 50,000 / mm3

  • Hb ≥ 8.0 g / dl

  • Good performance status (ECOG 0-1)

Exclusion

Exclusion Criteria:

  • Brain metastasis

  • Diffuse peritoneal carcinomatosis

  • Malignant pleural effusion

  • History of previous salvage radiotherapy for recurrent lesions

  • History of other malignancy or severe/unstable medical condition

Study Design

Total Participants: 107
Study Start date:
May 10, 2018
Estimated Completion Date:
May 09, 2023

Connect with a study center

  • Severance Hospital

    Seoul, Korea 120-752
    Korea, Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.